Ophthalmic medical technology company Glaukos Corporation recently reported favorable results for a study of its iStent® Trabecular Micro-Bypass stents as an initial treatment for glaucoma.
The study included 101 phakic subjects with primary open-angle glaucoma (POAG) who had never undergone any glaucoma treatment. The subjects either received two iStents or topical ocular hypotensive medication therapy (travoprost).
According to Glaukos, newly diagnosed POAG patients achieved a 43 percent reduction in mean intraocular pressure (IOP) to 14.6 mm Hg through 36 months following implantation of two iStent Trabecular Micro-Bypass stents in a standalone procedure. Eleven percent of eyes in the stent group required additional topical mediccation therapy, compared to 23 percent in the travopost group. And within the stent group, 91 percent of eyes had an IOP ≤ 18 mm Hg without additional topical medication therapy, compared to 79 percent of eyes in the travoprost group.
And study was recently published in the journal Ophthalmology and Therapy.
Photo courtesy Glaukos.
Click here to read the full press release.
Source: Glaukos Corporation